<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/TG-Therapeutics-Inc-US88322Q1085">TG Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/08/03/3337372/8790/en/tg-therapeutics-reports-second-quarter-2026-financial-results-and-raises-briumvi-revenue-guidance.html">TG Therapeutics meldet Finanzresultate für das zweite Quartal 2026 und erhöht Prognose für BRIUMVI®‑Umsatz</a>
    </div>

      <div class="me-0 me-md-5">
        Gesamtumsatz weltweit im zweiten Quartal 2026 von etwa 240 Mio. USD, einschließlich BRIUMVI U.S. Netto‑Produktumsatz von etwa 228 Mio. USD. Anhebung der Gesamtjahresprognose 2026 auf etwa 950 Mio. USD und Anhebung der Prognose für den BRIUMVI U.S. Netto‑Produktumsatz 2026 auf etwa 890–905 Mio. USD. Telefonkonferenz findet heute, Montag, 3. August 2026, um 8:30 Uhr ET statt. NEW YORK, 3. Aug. 20...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/TG-Therapeutics-Inc-US88322Q1085">TG Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/07/06/3322333/8790/en/TG-Therapeutics-Announces-Initiation-of-Phase-2-Trial-Evaluating-BRIUMVI-in-Patients-with-Treatment-Resistant-Schizophrenia.html">TG Therapeutics kündigt Beginn einer Phase-2-Studie zur Evaluierung von BRIUMVI bei Patienten mit therapieresistenter Schizophrenie an</a>
    </div>

      <div class="me-0 me-md-5">
        Phase-2-Studie zur Bewertung der Wirkungen einer B-Zell-Depletion mit BRIUMVI bei etwa 60 Patienten mit therapieresistenter Schizophrenie auf Grundlage aufkommender Hinweise, die Immundysfunktion mit der Erkrankung bei einer Teilmenge von Patienten in Verbindung bringen Phase-2-Studie zur Bewertung der Wirkungen einer B-Zell-Depletion mit BRIUMVI bei etwa 60 Patienten mit therapieresistenter Sc...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/TG-Therapeutics-Inc-US88322Q1085">TG Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/research/the-new-america/tg-therapeutics-stock-briumvi-myasthetia-gravis-subcutaneous/">TG Therapeutics Stock Is On A Hot Streak: Why It&#39;s Up 70% And Climbing</a>
    </div>

      <div class="me-0 me-md-5">
        TG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/TG-Therapeutics-Inc-US88322Q1085">TG Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/09/3308725/8790/en/TG-Therapeutics-Announces-Positive-Topline-Phase-1-Data-for-Subcutaneous-BRIUMVI-in-Patients-with-Myasthenia-Gravis-and-Initiation-of-Potential-Registration-Directed-Randomized-Pha.html">TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial</a>
    </div>

      <div class="me-0 me-md-5">
        82% of subjects achieved an MCID in their MG-ADL with a mean &gt;4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/TG-Therapeutics-Inc-US88322Q1085">TG Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/03/3305943/8790/en/TG-Therapeutics-Announces-Positive-Results-from-Phase-1-Trial-Evaluating-Subcutaneous-BRIUMVI-ublituximab-xiiy.html">TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)</a>
    </div>

      <div class="me-0 me-md-5">
        Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/TG-Therapeutics-Inc-US88322Q1085">TG Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/02/3305039/8790/en/TG-Therapeutics-to-Participate-in-the-Goldman-Sachs-47th-Annual-Healthcare-Conference.html">TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company&#39;s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th Annual Healthcare Conference, being held at the Loews Miami Beach Hotel, in Miami Beach, Florida on June 8-10, 2026.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/TG-Therapeutics-Inc-US88322Q1085">TG Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/01/3304240/8790/en/TG-Therapeutics-Announces-Publication-of-Post-Hoc-Data-from-the-Phase-3-ULTIMATE-I-II-Trials-in-Treatment-Naive-Patients-with-Relapsing-Forms-of-MS-Published-in-Frontiers-in-Immuno.html">TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I &amp; II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology</a>
    </div>

      <div class="me-0 me-md-5">
        Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease activity (NEDA-3) in treatment naïve patients supporting early use of high-efficacy therapy NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today a...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/TG-Therapeutics-Inc-US88322Q1085">TG Therapeutics, Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/28/3302711/8790/en/TG-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html">TG Therapeutics to Participate in the Jefferies Global Healthcare Conference</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company&#39;s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 2-4, 2026.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/TG-Therapeutics-Inc-US88322Q1085/load_more?page=3">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>